Literature DB >> 25479137

Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis.

Lee J L Markwick1, Antonio Riva2, Jennifer M Ryan3, Helen Cooksley2, Elena Palma2, Tom H Tranah3, Godhev K Manakkat Vijay3, Nikhil Vergis4, Mark Thursz4, Alex Evans5, Gavin Wright6, Sarah Tarff6, John O'Grady3, Roger Williams2, Debbie L Shawcross3, Shilpa Chokshi7.   

Abstract

BACKGROUND & AIMS: Susceptibility to bacterial infection is a feature of alcohol-related liver disease. Programmed cell death 1 (PD1), the T-cell immunoglobulin and mucin domain-containing protein 3 (TIM3, also known as hepatitis A virus cellular receptor 2), and their respective ligands-CD274 (also known as PD ligand 1 [PDL1]) and galectin-9-are inhibitory receptors that regulate the balance between protective immunity and host immune-mediated damage. However, their sustained hyperexpression promotes immune exhaustion and paralysis. We investigated the role of these immune inhibitory receptors in driving immune impairments in patients with alcoholic liver disease.
METHODS: In a prospective study, we collected blood samples from 20 patients with acute alcoholic hepatitis (AAH), 16 patients with stable advanced alcohol-related cirrhosis, and 12 healthy individuals (controls). Whole blood or peripheral blood mononuclear cells were assessed for expression of PD1, PDL1, TIM3, galectin-9, and Toll-like receptors on subsets of innate and adaptive immune effector cells. We measured antibacterial immune responses to lipopolysaccharide (endotoxin) using ELISpot assays, and used flow cytometry to quantify cytokine production, phagocytosis, and oxidative burst in the presence or absence of blocking antibodies against PD1 or TIM3.
RESULTS: Antibacterial innate and adaptive immune responses were greatly reduced in patients with AAH, compared with controls, and patients with alcohol-related cirrhosis had less severe dysfunctions in innate immune effector cells and preserved functional T-cell responses. Fewer T cells from patients with AAH produced interferon gamma in response to lipopolysaccharide, compared with controls. In addition, patients with AAH had greater numbers of interleukin 10-producing T cells, and reduced levels of neutrophil phagocytosis and oxidative burst in response to Escherichia coli stimulation, compared with controls. T cells from patients with AAH, but not alcohol-related cirrhosis, expressed higher levels of PD1 and PDL1, or TIM3 and galectin-9, than T cells from controls. Antibodies against PD1 and TIM3 restored T-cell production of interferon gamma, reduced the numbers of interleukin 10-producing T cells, and increased neutrophil antimicrobial activities. Circulating levels of endotoxin in plasma from patients with AAH caused over expression of immune inhibitory receptors on T cells via Toll-like receptor 4 binding to CD14(+) monocytes.
CONCLUSIONS: Antibacterial immune responses are impaired in patients with AAH. Lymphocytes from these patients express high levels of immune inhibitory receptors, produce lower levels of interferon gamma, and have increased IL10 production due to chronic endotoxin exposure. These effects can be reversed by blocking PD1 and TIM3, which increase the antimicrobial activities of T cells and neutrophils.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alcoholism; Immune Regulation; Innate Immunity; TLR

Mesh:

Substances:

Year:  2014        PMID: 25479137     DOI: 10.1053/j.gastro.2014.11.041

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  79 in total

1.  Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice.

Authors:  Xianhong Du; Zhuanchang Wu; Yong Xu; Yuan Liu; Wen Liu; Tixiao Wang; Chunyang Li; Cuijuan Zhang; Fan Yi; Lifen Gao; Xiaohong Liang; Chunhong Ma
Journal:  Cell Mol Immunol       Date:  2018-05-07       Impact factor: 11.530

Review 2.  Galectin-9: Diverse roles in hepatic immune homeostasis and inflammation.

Authors:  Lucy Golden-Mason; Hugo R Rosen
Journal:  Hepatology       Date:  2017-05-27       Impact factor: 17.425

Review 3.  Inflammatory pathways in alcoholic steatohepatitis.

Authors:  Bin Gao; Maleeha F Ahmad; Laura E Nagy; Hidekazu Tsukamoto
Journal:  J Hepatol       Date:  2019-02       Impact factor: 25.083

4.  Alcoholic hepatitis: Can we outwit the Grim Reaper?

Authors:  Sakkarin Chirapongsathorn; Patrick S Kamath; Vijay Shah
Journal:  Hepatology       Date:  2015-05-26       Impact factor: 17.425

Review 5.  Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2018-04-18       Impact factor: 3.199

Review 6.  Acute on chronic liver failure in non-alcoholic fatty liver and alcohol associated liver disease.

Authors:  Ashwani K Singal; Patrick S Kamath
Journal:  Transl Gastroenterol Hepatol       Date:  2019-10-11

Review 7.  Grand Rounds: Alcoholic Hepatitis.

Authors:  Ashwani K Singal; Alexandre Louvet; Vijay H Shah; Patrick S Kamath
Journal:  J Hepatol       Date:  2018-06-13       Impact factor: 25.083

Review 8.  Immune dysfunction in acute alcoholic hepatitis.

Authors:  Ashwin D Dhanda; Peter L Collins
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 9.  New treatment options for alcoholic hepatitis.

Authors:  Saggere Muralikrishna Shasthry; Shiv Kumar Sarin
Journal:  World J Gastroenterol       Date:  2016-04-21       Impact factor: 5.742

Review 10.  Treatment of Severe Alcoholic Hepatitis.

Authors:  Mark Thursz; Timothy R Morgan
Journal:  Gastroenterology       Date:  2016-03-04       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.